TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a bioprocess optimization initiative intended to support the manufacturing infrastructure for its therapeutic pipeline and commercial exosome activities.
NurExone is collaborating with Austria-based Novasign GmbH (“Novasign”) on the initiative to apply Novasign’s bioprocess modeling platform to NurExone’s proprietary exosome production process and assess opportunities to support process optimization and a planned technology transfer to Exo-Top Inc., the Company’s wholly owned U.S. subsidiary (“Exo-Top”).